anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Dual antiplatelet therapy consisting of aspirin and a P2Y12 receptor antagonist is the cornerstone of treatment for secondary prevention of thrombotic events in patients with coronary artery disease. Recently, two new oral P2Y12 antagonists have been approved for clinical use: prasugrel, a third generation thienopyridine, and ticagrelor, a first in class cyclopentyltriazolopyrimidine (CPTP). These agents have been shown to be associated with more potent platelet inhibitory effects compared with clopidogrel. In addition, both agents have shown to be superior to clopidogrel in preventing recurrent ischemic events in the setting of acute coronary syndromes (ACS). Therefore, current guidelines recommend prasugrel or ticagrelor (as first line therapy according to European Society of Cardiology) in ACS patients undergoing percutaneous coronary intervention (PCI). Despite the broader indication for ticagrelor (also medically managed ACS) and its mortality benefit, prasugrel has a higher uptake than ticagrelor in the US market, likely due to its earlier approval. Further, implementation of prasugrel into institutional protocols, particularly for ST elevation myocardial infarction (STEMI) patients undergoing primary PCI, may also be a reason for the slow uptake of ticagrelor. However, many clinicians would indeed consider ticagrelor as the long-term treatment of choice for a variety of reasons. Therefore, understanding how to switch patients from prasugrel to ticagrelor is an unmet need of clinical interest. However, currently, there are no data on the pharmacodynamic (PD) effects of switching from prasugrel to ticagrelor. The proposed PD investigation will have a prospective, randomized, parallel design aimed to show that switching patients from prasugrel to ticagrelor provides similar levels of platelet inhibition. This study will provide insights on the PD effects of switching and will help clinicians to choose the most appropriate schema to avoid complications related to inadequate antiplatelet therapy in patients with coronary artery disease if switching from prasugrel to ticagrelor is desired.
Methods are disclosed for treating a subject with a tumor. These methods include administering to the subject a therapeutically effective amount of CD8 + CD39 + CD103 +  T cells. Methods also are disclosed for isolating a nucleic acid encoding a T cell receptor (TCR) that specifically binds a tumor cell antigen. These methods include isolating CD8 + CD39 + CD103 +  T cells from a sample from a subject with a tumor expressing the tumor cell antigen, and cloning a nucleic acid molecule encoding a TCR from the CD8 + CD39 + CD103 +  T cells. In addition, methods are disclosed for expanding CD8 + CD39 + CD103 +  T cells. In additional embodiments, methods are disclosed for determining if a subject with a tumor will respond to a checkpoint inhibitor. The methods include detecting the presence of CD8 + CD39 + CD103 +  T cells in a biological sample from a subject.
This study will take place in one outpatient dialysis clinic. The clinical trial will compare a standardized therapy dog interaction delivered twice weekly (based on pilot study outcomes detailed below) to usual care (e.g., no dog exposure) using a 1:1 randomized, 2-arm design. Subjective patient-reported outcomes \[PRO\] and routinely-tracked clinic data (e.g., missed visits) will be used. A total of 30 patients will be recruited then randomized 1:1 into 2 arms: control group with 0 dog visits (n = 15) and intervention group with 2 dog visits per week for 20 weeks (n = 15). The AAI is designed to promote patient comfort, uplift mood, and provide an opportunity for socialization. The nature of the dog interaction involves several different components, including but not limited to: petting the dog, talking to the dog, watching the dog do tricks, conversing with the dog handler, and being prompted to discuss any fond memories/stories of their own personal experiences with human-animal interactions. Regarding duration, the dog visits average 10 minutes but will be allowed to vary, and length of dog visits will be tracked. Each team (dog handler + dog) will have an assigned unique ID so that variation in dog is controlled for. This study will utilize trained certified dog handlers to deliver the intervention from reputable local and national pet therapy organizations. All dogs have gone through extensive training and behavioral assessment, will provide proper documentation, liability insurance, and vaccinations. All study procedures take place in the clinic waiting room. Patient-reported outcomes (PRO)s will be collected as pre-post data (before and after dog visit or lobby-as-usual control condition). All PROs will be collected electronically on iPads using REDcap. Regarding treatment adherence data, the clinic routinely tracks missed appointments and will report these metrics directly to research team. Patients will complete assessments 2 times per week for a total of 20 weeks. A short demographic questionnaire will be administered once at the first study visit. Also, patients will also undergo a monthly blood-draw providing 3mL of blood 1 time a month at the same time as their standard of care blood draw. This will be bio-banked in a repository for later ELISA analyses, which will focus on hormones related to stress and bonding (e.g., oxytocin, cortisol); this may provide insight into mechanistic biomarkers underpinning the human-animal bonding process. Lastly, qualitative focus groups with intervention group participants will be conducted post-trial to learn about their subjective experiences of the AAI.
PURPOSE:To provide the subject preventive and treating agent containing materials from sterilized bacterial cells, crushed materials thereof or cell wall component-containing materials prepared by fractionation of the crushed materials, excellent in safety and its effects. CONSTITUTION:One or more selected from materials e.g. obtained by heat- sterilizing the cells of bacteria belonging to the genus Bacillus, Brevibacterium, Corynebacterium, Escherichia, Lactobacillus, Streptococcus, Streptomyces or Biffidobacterium, a crushed-cell material obtained by mechanically crushing (e.g. French press or ultrasonic crusher) or enzymatically decomposing the above-mentioned bacterial cells, or cell wall component-containing materials obtained by fractionating (e.g. centrifugation or ultrafiltration) the above- mentioned crushed materials are used. The obtained materials are recommendably added to a feed for fishes or Crustacea in an amount of 0.01-5wt.%, preferably 0.05-1wt.% as dry material base.
This study aimed to estimate the frequency and overlap of cachexia, malnutrition, and sarcopenia in elderly patients with diabetes mellitus. Patients who were aged at least 65 years, had diabetes mellitus, and were regularly visiting the Ise Red Cross Hospital on an outpatient basis were included. The patients were assessed to determine whether they had cachexia, malnutrition, and sarcopenia according to the Asian Working Group for Cachexia criteria, the Global Leadership Initiative on Malnutrition criteria, and the Asian Working Group for Sarcopenia 2019 criteria. A total of 510 patients (310 men and 200 women) were analyzed in this study. Sarcopenia, cachexia, and malnutrition were found in 84 patients (16.4%), 40 patients (7.8%) (17.8% among patients with chronic diseases), and 110 patients (21.5%), respectively. Among patients with sarcopenia, the frequencies of cachexia and malnutrition were 30% and 71.4%, respectively. Among patients with cachexia, the frequencies of sarcopenia and malnutrition were 65% and 90%, respectively, and among those with malnutrition, the frequencies of sarcopenia and cachexia were 54% and 32.7%, respectively. The overlap among cachexia, malnutrition, and sarcopenia appears to be an important factor to be considered in the treatment of elderly patients with diabetes mellitus.
Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of BGs throughout the duration of the study.
A baseline series of brain function tests will be performed. Following this, participants will complete a 24 hour fluid and water rich food restriction on the day proceeding testing. Participants will then complete moderate to high intensity exercise in a hot/humid room to achieve 5% body mass loss. Once baseline core body temperature returns to baseline levels, the series of brain function tests will be performed. Participants will then consume a sports drink equal to the volume of sweat lost over the course of a 2 hour recover period. Following this, he series of brain function tests will be performed.
Bispectral index (BIS) was developed to monitor a patient's level of consciousness under general anesthesia. Several factors have been found to alter BIS readings without affecting the depth of anesthesia.Changing a patient's position (head up and head down) significantly affects the BIS values, which might affect the interpretation of anesthetic depth.

During esophageal cancer surgery, there were several factors which could affect to BIS values.First, the surgical positions are consisted with supine and lateral decubitus position more than 1 h. Thus, the investigators compare the BIS value of both side on supine and lateral decubitus position by both side approach. Second, the one lung ventilation was applied for surgical filed. It alters the oxygenation and the cerebral flow. Because of these effects, the BIS monitoring can differ by the period of surgery. Thus, in this study, the BIS value of both side monitor throughout the surgery.
The invention belongs to the field of traditional Chinese medicine, and discloses a traditional Chinese medicine for treating acute bronchitis. The medicine is composed of the following raw materials by weight: 8-12 grams of Rehmannia glutinosa, 8-12 grams of Trichosanthes kirilowii Maxim, 3-6 grams of Bulbus Fritillariae Cirrhosae, 5-10 grams of longan pulp, 5-10 gramsof dried tangerine peel, 8-12 grams of Platycodon grandiflorum and 3-8 grams of licorice. Preferably, the medicine comprises 10 grams of Rehmannia glutinosa, 10 grams of Trichosanthes kirilowii Maxim, 5 grams of Bulbus Fritillariae Cirrhosae, 8 grams of longan pulp, 8 grams of dried tangerine peel, 10 grams of Platycodon grandiflorum and 5 grams of licorice. The inventor conducts clinical observation and treatment on 210 cases of patients with acute bronchitis at the age of 30-54, wherein the patients comprise 102 males and 108 females; the treatment method is as below: adding water into the 7 herbs to 500 ml, soaking for an hour, boiling with strong fire, decocting for 3 h with slow fire, and removing the slag to obtain a filtrate of 450ml; and decocting each dose of medicine into 450ml, taking 150ml each time for 3 times a day for 3 consecutive days. According to the severity of the patient's condition, mild patients take a course of treatment, and severe patients take two courses of treatment; the clinical cure reaches 130 cases (61.9%), 51 cases show markedly effectiveness (24.3%), 28 cases show effectiveness (13.3%), and 1 case is invalid (0.5%); and the total effective rate is 99.5%. The invention has the advantages of reasonable prescription, no side effect, and obvious curative effect.
Participants will receive transdermal estradiol (100μg/day) for 3 weeks. Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
Depression and diabetes are closely linked; however, the pathogenesis of depression associated with diabetes is unclear, and there are no clinically effective antidepressant drugs for diabetic patients with depression. Bavachin is an important active ingredient in Fructus Psoraleae. In this study, we evaluated the anti-neuroinflammatory and antidepressant effects associated with diabetes and the molecular mechanisms of bavachin in a streptozotocin-induced diabetes mouse model. We found that bavachin clearly decreased streptozotocin (STZ)-induced depressive-like behaviors in mice. It was further found that bavachin significantly inhibited microglia activation and the phosphorylation level of PKCδ and inhibited the activation of the NF-κB pathway in vivo and in vitro. Knockdown of PKCδ with siRNA-PKCδ partially reversed the inhibitory effect of bavachin on the NF-κB pathway and the level of pro-inflammatory factors. We further found that PKCδ directly bound to bavachin based on molecular docking and pull-down assays. We also found that bavachin improved neuroinflammation-induced neuronal survival and functional impairment and that this effect may be related to activation of the ERK and Akt pathways mediated by the BDNF pathway. Taken together, these data suggested that bavachin, by targeting inhibition PKCδ to inhibit the NF-κB pathway, further reduced the inflammatory response and oxidative stress and subsequently improved diabetic neuronal survival and function and finally ameliorated diabetes-induced depressive-like behaviors in mice. For the first time, we found that bavachin is a potential agent for the treatment of diabetes-associated neuroinflammation and depression and that PKCδ is a potential target for the treatment of diabetes-associated neuroinflammation, including depression.
1413382 Water-insolubilized peptide preparations BAYER AG 29 March 1973 [30 March 1972] 15115/73 Addition to 1413381 Heading C3H [Also in Division C2] A water-insoluble preparation comprises a peptide material, e.g. a protein, enzyme, enzyme inhibitor or amino acid bound to a crosslinked copolymer comprising the copolymerized residues: A: 0À1 to 90 wt. per cent of at least one α,#-mono-olefinically unsaturated dicarboxylic anhydride having 4 to 9 carbon atoms; B: 35 to 90 wt. per cent of at least one di- and/or polyacrylate or methacrylate of a diol and/or a polyol; and C: 5 to 60 wt. per cent of at least one hydrophilic monomer not as defined under B. The copolymer having a bulk volume of 1À4 to 30 ml./g., and a specific area of 1 to 500 m.<SP>2</SP>/g. and containing, after hydrolysis of the anhydride groups, 0-01 to 14 m.equiv. of acid per gram. The copolymerized residues A may be derived from at least one of maleic, itaconic and citraconic anhydrides and the copolymerized residues B may be at least one of the acrylates derived from diacrylates and dimethacrylates of diols having 2 to 4 carbon atoms, dimethacrylates of reaction products of 1 mole of diols having 2 to 4 carbon atoms with 1 to 10 moles of at least one alkylene oxide with 2 to 4 carbon atoms, and trimethylolpropane trimethacrylate, and the copolymerized units C of the copolymer are derived from at least one hydrophilic monomer containing a carboxyl, aminocarbonyl, sulpho or sulphamoyl group. Preferably residues A are of maleic anhydride, residues B are of ethylene glycol, diethylene glycol, triethylene glycol and tetraethylene glycol dimethacrylates, trimethylolpropane trimethacrylates and mixtures thereof, and residues C are selected from methacrylic acid, acrylic acid, methacrylamide, N-methoxymethyl acrylamide, N-methoxymethylmethacrylamide, N-vinyl pyrrolidone and mixtures thereof.
BACKGROUND: Depression has a significant effect on cardiovascular disease (CVD), but uncertainties persist regarding which modifiable risk factors mediate the causal effects. We aim to determine whether depression is causally linked to CVD and which modifiable risk factors play potential mediating roles.
METHODS: We used a two-sample Mendelian randomization (MR) approach and NHANES 2007-2018 data to estimate the effects of depression on various CVD cases and investigated 28 potential mediators of the association between depression and CVD.
RESULTS: The results of our MR analysis indicated that genetically determined depression was associated with increased risk of several CVD, including coronary heart disease (odds ratio (OR) = 1.14; 95% confidence interval (CI): 1.05,1.22), myocardial infarction (OR = 1.19; 95% CI, 1.09,1.31), atrial fibrillation (OR = 1.14; 95% CI, 1.06,1.22), and stroke (OR = 1.13; 95% CI, 1.05,1.22). However, there was no causal association between depression and heart failure. Four out of 28 cardiometabolic risk factors, including hyperlipidemia, hypertension, diabetes, and prescription opioid use, were identified as mediators of the association between depression and various CVDs. Observational association analyses from NHANES data yielded consistent results.
CONCLUSION: Our findings demonstrated that depression has a causal detrimental effect on various CVDs. Four causal mediators (hyperlipidemia, hypertension, diabetes, and prescription opioid use) were screened to explain the causal effect. Implementing targeted management strategies for these risk factors may be warranted to mitigate the public health burden of CVD among individuals with depression.
The present invention relates to an application compliance device (1) for monitoring a customized dosage regime of a skin care product provided in a container device (20). The device comprises a housing (2) having an inner wall (2a) and an outer wall (2b), and defining a top opening (2c) with a first diameter (D1) for receiving the container device (20) in the application compliance device (1). The device further comprises a control unit (8), a sensor unit (10) configured to sense a quantity of the skin care product administered from the container device (20), when being received in the application compliance device (1), and a signal unit (7). The sensor unit (10) and the signal unit (7) are coupled to the control unit (8). The housing (2) houses the control unit (8), the sensor unit (10) and the signal unit (7). The control unit (8) is configured to evaluate a quantity signal received from the sensor unit (10) to determine an administered dosage quantity, to control the signal unit (7) to generate a compliant signal if the administered dosage quantity is compliant with the customized dosage regime, to control the signal unit (7) to generate a partly compliant signal if the administered dosage quantity is not compliant with the dosage regime for a first time, and to control the signal unit (7) to generate a warning signal if the administered dosage quantity is not compliant with the dosage regime for a second time. The invention also relates to a method of monitoring such a customized dosage regime and to methods for determining a therapy surface on a patient's skin.
Annually, between 100,000 to 140,000 children present to the emergency department for concussion in the United States.1 The Centers for Disease Control now estimates that 1.6 - 3.8 million sports related concussions occur each year in the United States. A large proportion of these patients have enduring cognitive and neurobehavioral problems. Concussion is a heterogeneous insult to the brain that precipitates a complex pathophysiological process that can result in a cascade of deleterious side effects. At present, there are no proven therapies to mitigate or prevent the neurocognitive and neurobehavioral consequences of concussions. The limbic hippocampus, a brain structure crucial for learning and memory, is often damaged in concussion. In preclinical studies in our laboratory, analysis of ipsilateral hippocampi isolated from mice after traumatic brain injury (TBI) demonstrated that only the concentrations of the three BCAA's (valine, isoleucine, and leucine) were significantly altered (reduced) after injury. When these brain-injured animals received dietary supplementation with BCAA's, the concentrations of these amino acids were restored in the injured hippocampus and the injured animals demonstrated significant cognitive improvement to levels comparable to those obtained in non-injured control animals. In light of these results and the increasing awareness and morbidity associated with concussion, we are proposing a pilot therapeutic exploratory clinical trial to determine the effects of BCAA's in reducing the neurocognitive side effects of concussion injury.
Participants in ratio of 3:1 will receive 3.0 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.
BACKGROUND: The increasing prevalence of childhood obesity has become an urgent public health problem, evidence showed that intervention for childhood obesity bring enormous health benefits. However, an effective individualized intervention strategy remains to be developed, and the accompanying remission of related complications, such as nonalcoholic fatty liver disease (NAFLD), needs to be assessed. This study aimed to develop an m-Health-assisted lifestyle intervention program targeting overweight/obese children and assess its effectiveness on indicators of adiposity and NAFLD.
METHODS: This is a cluster-randomized controlled trial that conducted in children with overweight/obesity in Ningbo city, Zhejiang Province, China. Students in Grade 3 (8-10 years old) were recruited from six primary schools, with three be randomized to intervention group and three to usual practice group. The intervention program will last for one academic year and consists of health education, dietary guidance, and physical activity reinforcement. This program is characterized by encouraging four stakeholders, including School, Clinic, famIly, and studENT (SCIENT), to participate in controlling childhood obesity, assisted by m-Health technology. Assessments will be conducted at baseline and 3 months, 9 months, 24 months, and 36 months after baseline. The primary outcome will be the differences between the two groups in students' body mass index and fatty liver index at the end of the intervention (9 months after baseline). During the implementation process, quality control methods will be adopted.
DISCUSSION: The program will test the effectiveness of the m-Health-assisted lifestyle intervention on children with obesity and NAFLD. The results of this study will provide evidence for establishing effective lifestyle intervention strategy aimed at childhood obesity and NAFLD and may help develop guidelines for the treatment of obesity and NAFLD in Chinese children.
TRIAL REGISTRATION: Clinicaltrials.gov NCT05482191. Registered on July 2022.
In vitro and in vivo performance of O2/CO2 reduced red blood cells produced with the Hemanext System will be used to demonstrate the acceptability the final product for clearance. To accomplish this, the study will require a total of 100 studyevaluable donors. completing the study. The study entails a randomized, paired, 2-x-2 crossover design where every study donor (n = 10093) evaluable study donors who completes the study will donate a total of two whole blood units with individual units being donated at least 56 days (8 weeks) apart. One unit will be used as the test and the other unit will be used for the control. The order in which the IP and the CP will be used to collect, filter and store the whole blood and appropriate blood products (within the context of the crossover design) will be randomized.